News

Fulvestrant bests anastrozole in advanced breast cancer

Publish date: December 18, 2014

 

AT SABCS 2014

References

The FIRST trial was funded by AstraZeneca. Dr. Robertson reported serving as a consultant to that company as well as Bayer HealthCare and receiving research funding from both companies along with Amgen and Novartis.

bjancin@frontlinemedcom.com

Pages

Recommended Reading

VIDEO: High TILs associated with less efficacy from trastuzumab
MDedge ObGyn
North America has highest rate of obesity-related cancers
MDedge ObGyn
Adjuvant capecitabine adds no advantage to bisphosphonate in elderly breast cancer patients
MDedge ObGyn
VIDEO: Multidisciplinary panel addresses role of anesthesia, analgesics in patient outcomes
MDedge ObGyn
SOFT trial endorses selective ovarian suppression in early breast cancer
MDedge ObGyn
VIDEO: What was the most interesting thing you learned at the meeting?
MDedge ObGyn
20 years after initiating preventive tamoxifen, less breast cancer but no survival benefit
MDedge ObGyn
AI-induced symptoms don’t predict survival
MDedge ObGyn
Acupuncture beats gabapentin for hot flashes in RCT
MDedge ObGyn
Genetic test predicts 10-year risk of DCIS recurrence
MDedge ObGyn